Drug Trial Radar · NCT06454188
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 3, 2024
Primary completion
Sep 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- CARE ARTHRITIS LTD.Industry
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Jun 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)
Conditions
- Psoriatic Arthritis
- Spondyloarthritis, Axial
Interventions
Upadacitinib 15 MG [Rinvoq]Drug
15mg tablet once per day.
PlaceboDrug
15mg tablet once per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the (SPARCC) MRI inflammation score (for SIJ and spine) at 12 weeks of therapy with upadacitinib vs placebo in the DMARD-IR (conventional and/or biologic) subgroupTime frame: 12 weeks
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
The Ottawa Hospital Research Institute
Ottawa, Ontario, Canada · Recruiting
Groupe de Recherche en Maladies Osseuses (G.R.M.O.) Inc.
Québec, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.